

To NASDAQ OMX Copenhagen A/S

Company release no. 8/2012

Hørsholm
27 March 2012

Annual general meeting of ALK-Abelló A/S and the first meeting of the Board of Directors held on 27 March 2012

Page 1/2

The annual general meeting of ALK held on 27 March 2012 transacted the following business:

- Adoption of the annual report 2011 and discharge of the Board of Directors and Board of Management.
- Declaration of an ordinary dividend of DKK 5.00 per A/B share of DKK 10.
- Approval of the remuneration to the Board of Directors for the present year. The remuneration remains unchanged compared with 2011.
- For the period up to the next annual general meeting, the Board of Directors was authorised to let the company acquire own B shares with a nominal value of up to 10% of the share capital at the market price for B shares on the date of acquisition, subject to a deviation of up to 10%.
- For the period up to and including the day of the annual general meeting to be held in 2013, the Board of Directors was authorised to increase the company's share capital by issue of new shares with a nominal value of up to DKK 10,128,360, equivalent to A shares with a nominal value of up to DKK 920,760 and B shares with a nominal value of up to DKK 9,207,600.
- Approval of minor adaptations of the guidelines for incentive pay to members of the Board of Management.
- Thorleif Krarup, Lars Holmqvist, Anders Gersel Pedersen, Steen Riisgaard and Jes Østergaard were re-elected to the Board of Directors. Christian Dyvig, Chief Executive Officer of the Lundbeck Foundation, was newly elected to the Board of Directors. Brian Petersen did not seek re-election.
- DELOITTE Statsautoriseret Revisionspartnerselskab was re-appointed as the company's auditor.

New Chairman and Vice Chairman of the Board of Directors

Following the annual general meeting, the Board of Directors held its first meeting. Steen Riisgaard was elected Chairman and Christian Dyvig was elected Vice Chairman.

The newly elected Chairman, Steen Riisgaard, CEO of Novozymes, says: "These years, ALK is investing considerably in the development of new products that may change the treatment of allergy and asthma. I look forward to contributing to ALK's generation of considerable growth in the years ahead through continued global commercialisation of allergy vaccination."

The following were re-elected to the Board of Directors' audit committee: Lars Holmqvist (chairman) and Thorleif Krarup. The remuneration committee remains unchanged, comprising the following members: Jes Østergaard (chairman), Anders Gersel Pedersen and Steen Riisgaard.

ALK-Abelló A/S

Steen Riisgaard
Chairman

For further information please contact:

Jens Bager, President and CEO, tel. +45 4574 7576